期刊文献+

LC-MS/MS定量测定人体血浆中阿托伐他汀浓度 被引量:5

Quantitative Determination of the Atorvastatin Concentration in Healthy Human Plasma by LC-MS/MS
原文传递
导出
摘要 目的:建立定量测定人体血浆中阿托伐他汀浓度的HPLC-MS/MS的方法。方法:以吲哚美辛为内标,采用Shim-pack VP-ODS柱(150×2.0 mm I.D.,5μm,日本Shimadzu Technologies Inc.公司)为固定相;乙腈-0.5%甲酸溶液(90:10,v/v)为流动相,流速为0.3 ml/min;通过电喷雾离子源(ESI),以正离子多反应监测模式进行检测。阿托伐他汀与内标用于检测的离子对分别为m/z 559.4 m/z 250.3和m/z 358.3 m/z 139.2。结果:阿托伐他汀在0.10~20.00 ng/ml范围内与峰面积比值线性范围良好(r=0.9962),定量下限为0.10 ng/ml,日内日间精密度的RSD均小于12%,平均回收率大于71%。结论:所建方法准确度高,方法灵敏,专属性强且操作简便,可适用于阿托伐他汀的血药浓度测定和临床药代动力学研究。 Objective: To establish the HPLC-MS/MS method to quantitatively determine the concentration of atorvastatin in healthy human plasma.Methods: The concentration was detected by Multiple Reaction Monitoring(MRM) in positive mode using Electrospray Ionization(ESI) source,with indomethacin as internal standard,Shim-pack VP-ODS(150×2.0 mm I.D.,5 μm,Shimadzu Technologies Inc.,Japan) as immobile phase and Acetonitrile-0.5 % Formic Acid aqueous solution as mobile phase(the flow rate was 0.3 ml/min).The ion pair was m/z 559.4 m/z 250.3 for atorvastatin and m/z 358.3 m/z 139.2 for indomethacin.Results: The calibration curve for plasma atorvastatin was linear in the range of 0.10~20.00 ng/ml(r=0.9962),the lower limit of quantitation was 0.10 ng/ml,the inter-and intra-day precision(RSD) were both less than 12 %.The average recovery rate was above 71 %.Conclusion: This method is accurate,sensitive,specific and convenient,and could be used in the determination of plasma atorvastatin concentration and the clinical study of its pharmacokinetics.
机构地区 解放军第 解放军第
出处 《现代生物医学进展》 CAS 2013年第13期2565-2569,共5页 Progress in Modern Biomedicine
基金 国家"十二五"重大专项(2012ZX10002003-004-006)
关键词 阿托伐他汀 LC-MS MS 血浆药物浓度 Atorvastatin LC-MS/MS Plasma concentration
  • 相关文献

参考文献7

二级参考文献51

共引文献92

同被引文献32

  • 1邸晓辉,杨永革,梅巍,刘静,许雪廷.阿托伐他汀钙胶囊的人体生物等效性研究[J].解放军药学学报,2005,21(4):262-265. 被引量:8
  • 2SHIN J, PAULY DF, PACANOWSKI MA, et al. Effect of cytochrome 17450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin[J]. Pharmacotherapy, 2011, 31(10) : 942-950.
  • 3FURMAN A, MEIER JL, MALMSTROM RA, et al. Comparative efficacy of ezetimibe/simvastatin, rosuvastatin, and atorvastatin in uncontrolled hyperlipidemia patients [J]. Am J Manag Care,2011, 17(8): 538-544.
  • 4BULLEN WW, MILLER RA, HAYES RN. Development and validation of a high-performance liquid chromatography tandem mass spectrometry assay for atorvastatin, ortho- hydroxy atorvastatin, and para-hydroxy atorvastatin in human, dog, and rat plasma[J]. J Am Soc Mass spectrom, 1999, 10(1 ): 55-66.
  • 5JOCOBSEN W, KUHN B, SOLDNER A, et al. Lactonization is the critical first step in the disposition of the 3- hydroxy- 3- methylglutaryl- CoA reductase inhibotor atorvastatin [J]. Drug Metab Dispos, 2000, 28 ( 11 ) : 1369-1378.
  • 6LIU YM, PU HH, LIU GY, et al. Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10 - mg tablets: A single - dose, randomized - sequence, open - label, two-period crossover study in healthy fasted Chinese adult males[J]. Clin Ther, 2010, 32(7): 1396-1407.
  • 7LENNERNAS H. Clinical pharmacokineties of atorvastatin [J]. Clin Pharmacokinet, 2003, 42(13): 1141-1160.
  • 8RAMAKRISHNA NV, KOTESHWARA M, VISHWOTTAM KN, et al. Simple, sensitive and rapid LC- MS- MS method for the quantitation of cerivastatin in human plasma- application to pharmacokinetic studies[J]. J Pharma Biomed Anal, 2004, 36 (3): 505-515.
  • 9窦宇红,吴雄君,蒋艳.RP-HPLC法测定阿托伐他汀在新西兰兔体内的药代动力学[J].现代生物医学进展,2010,10(8):1443-1445. 被引量:4
  • 10惠春,林大专,孙莹.阿托伐他汀致不良反应24例文献分析[J].中国药房,2010,21(44):4189-4191. 被引量:13

引证文献5

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部